BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30644636)

  • 1. A comparative study of confidence intervals to assess biosimilarity from analytical data.
    Quiroz J; Montes R; Shi H; Roychoudhury S
    Pharm Stat; 2019 May; 18(3):316-328. PubMed ID: 30644636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous confidence interval methods for analytical similarity assessment.
    Zheng J; Yin D; Yuan M; Chow SC
    J Biopharm Stat; 2019; 29(5):920-940. PubMed ID: 31454290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
    Yang H; Novick S; Burdick RK
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
    Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
    MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
    Zeng D; Pan J; Hu K; Chi E; Lin DY
    J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.
    Zhang N; Yang J; Chow SC; Chi E
    J Biopharm Stat; 2014; 24(6):1239-53. PubMed ID: 25036940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of tolerance intervals for assessing biosimilarity.
    Chen C; Hsiao CF
    Stat Med; 2020 Nov; 39(26):3806-3822. PubMed ID: 32754932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical considerations regarding correlated lots in analytical biosimilar equivalence test.
    Shen M; Wang T; Tsong Y
    J Biopharm Stat; 2017; 27(2):213-219. PubMed ID: 27906604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical Similarity Assessment in Biosimilar Studies.
    Chow SC; Song F; Bai H
    AAPS J; 2016 May; 18(3):670-7. PubMed ID: 26873509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparability of critical quality attributes for establishing biosimilarity.
    Liao JJ; Darken PF
    Stat Med; 2013 Feb; 32(3):462-9. PubMed ID: 22903263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical assessment of biosimilarity based on relative distance between follow-on biologics.
    Kang SH; Chow SC
    Stat Med; 2013 Feb; 32(3):382-92. PubMed ID: 22941672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of 95% CI or 90% CI for drug product development - a controversial issue?
    Chow SC; Zheng J
    J Biopharm Stat; 2019; 29(5):834-844. PubMed ID: 31454298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Bootstrapping Test for Analytical Biosimilarity.
    Zahel T
    AAPS J; 2022 Oct; 24(6):112. PubMed ID: 36271265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modified Wald test for reference scaled assessment of analytical equivalence.
    Weng YT; Tsong Y; Shen M; Wang C
    J Biopharm Stat; 2019; 29(6):1068-1081. PubMed ID: 30829123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
    Kwon O; Joung J; Park Y; Kim CW; Hong SH
    Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size requirement in analytical studies for similarity assessment.
    Chow SC; Song F; Bai H
    J Biopharm Stat; 2017; 27(2):233-238. PubMed ID: 27935446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the establishment of equivalence acceptance criterion in analytical similarity assessment.
    Wang T; Chow SC
    J Biopharm Stat; 2017; 27(2):206-212. PubMed ID: 28051920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some thoughts on the QR method for analytical similarity evaluation.
    Son S; Oh M; Choo M; Chow SC; Lee SJ
    J Biopharm Stat; 2020 May; 30(3):521-536. PubMed ID: 32089068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.